BRAF and glycogen storage disease VI: The TRIPLETE study compared a modified schedule of FOLFOXIRI plus panitumumab to FOLFOX plus panitumumab as first-line therapy for RAS/BRAF wild-type mCRC patients, the majority of whom exhibited multiple metastatic sites (52%), with only 38% of patients having liver-only disease [22].